Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$53.88 USD
+1.11 (2.10%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $53.90 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Crinetics Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 559 | 334 | 334 | 171 | 118 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 16 | 11 | 11 | 7 | 5 |
Total Current Assets | 574 | 345 | 345 | 177 | 123 |
Net Property & Equipment | 11 | 4 | 3 | 3 | 4 |
Investments & Advances | 0 | 0 | 1 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 2 | 1 | 1 | 1 |
Total Assets | 635 | 352 | 351 | 183 | 130 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 23 | 15 | 8 | 6 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 9 | 7 | 4 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 3 | 1 | 1 | 1 |
Total Current Liabilities | 44 | 28 | 16 | 10 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 6 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 96 | 36 | 19 | 15 | 13 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1,192 | 759 | 608 | 337 | 211 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -654 | -439 | -275 | -168 | -94 |
Other Equity | 1 | -4 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 539 | 316 | 332 | 169 | 117 |
Total Liabilities & Shareholder's Equity | 635 | 352 | 351 | 183 | 130 |
Total Common Equity | 539 | 316 | 332 | 169 | 117 |
Shares Outstanding | 66.80 | 53.70 | 47.50 | 32.90 | 24.20 |
Book Value Per Share | 8.07 | 5.89 | 6.99 | 5.13 | 4.84 |
Fiscal Year End for Crinetics Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 863 | 901 | 559 | 555 | 265 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 12 | 16 | 16 | 21 | 20 |
Total Current Assets | 875 | 917 | 574 | 576 | 285 |
Net Property & Equipment | 12 | 12 | 11 | 10 | 3 |
Investments & Advances | 0 | 0 | 0 | 5 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 3 | 3 | 3 | 4 |
Total Assets | 936 | 978 | 635 | 642 | 293 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 24 | 29 | 23 | 22 | 21 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 20 | 15 | 15 | 13 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 2 | 2 | 2 | 2 |
Total Current Liabilities | 54 | 52 | 44 | 40 | 33 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 5 | 5 | 5 | 5 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 105 | 103 | 96 | 94 | 39 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1,626 | 1,595 | 1,192 | 1,142 | 792 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -795 | -721 | -654 | -594 | -536 |
Other Equity | 0 | 0 | 1 | -1 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 831 | 875 | 539 | 548 | 254 |
Total Liabilities & Shareholder's Equity | 936 | 978 | 635 | 642 | 293 |
Total Common Equity | 831 | 875 | 539 | 548 | 254 |
Shares Outstanding | 78.80 | 78.70 | 66.80 | 54.60 | 54.00 |
Book Value Per Share | 10.54 | 11.12 | 8.07 | 10.03 | 4.71 |